PTO/SB/08a (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

	Application Number		10516705
	Filing Date		2004-12-02
INFORMATION DISCLOSURE	First Named Inventor	T. Ha	ara
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Unit		1645
	Examiner Name	tba	A control of the cont
	Attorney Docket Numb	er	3056 US0P
<u> </u>			

U.S.PATENTS							Remove			
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue D	ate	Name of Pate of cited Docu	entee or Applicant ment	Releva	Columns,Lines w nt Passages or R s Appear	
	1									
If you wist	n to ac	dd additional U.S. Pater	nt citatio	n informa	ation pl	ease click the	Add button.		Add	
			U.S.P	ATENT	APPLIC	CATION PUBL	LICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publica Date	tion	Name of Pate of cited Docu	entee or Applicant ment	Releva	Columns,Lines w nt Passages or R s Appear	
	1									
If you wisl	h to ac	dd additional U.S. Publi	shed Ap	plication	citation	n information p	please click the Add	button	Add	•
				FOREIG	N PAT	ENT DOCUM	ENTS		Remove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²	· I	Kind Code ⁴	Publication Date	Name of Patented Applicant of cited Document	e or V F	Pages,Columns,L where Relevant Passages or Rele Figures Appear	T5
LAB	1	EP 1 466 902	JР			2004-10-13	Takeda Chemical Industries, Ltd.			
If you wis	h to a	dd additional Foreign P	atent Do	cument	citation	information pl	ease click the Add	button	Add	
			МОМ	I-PATEN	IT LITE	RATURE DO	CUMENTS		Remove	
Examiner Initials* Cite No Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.							m T5			

/Lynn Bristol/

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Not for submission under 37 CFR 1.99)

Application Number		10516705	
Filing Date		2004-12-02	
First Named Inventor	T. Ha	ara	
Art Unit		1645	
Examiner Name tba			
Attorney Docket Number		3056 US0P	

7	B	1		GOTTLIEB, B., et al., "Update of the Androgen Receptor Gene Mutations Database", Human Mutation, (1999), Vol. 14, pages 103-114				
		2		, T., et al., "Novel Mutations of Androgen Receptor: Aome", Cancer Research, (2003), Vol. 63, No.1, pages		iide withdrawal		
		3	KOKONTIS, J., "Progression of LNCaP Prostate Tumor Cells during Androgen Deprivation: Hormone-Independent Growth, Repression of Proliferation by Androgen, and Role for p27Kip1 in Androgen-Induced Cell Cycle Arrest", Molecular Endocrinology, (1998), Vol. 12, pages 941-953					
		4	BENTEL, J., et al., "Androgen Receptor Expression in Primary Prostate Cancers of Lobund-Wistar Rats and in Tumor-Deprived Cell Lines", In Vitro Cellular & Developmental Biology- Animal, (1999), Vol. 35, No. 10, pages 655-662					
		5	ZHAO, X., et al., "Two Mutations Indentified in the Androgen Receptor of the New Human Prostate Cancer Cell Line MDA PCA 2A", The Journal of Urology, (1999), Vol. 162, pages 2192-2199					
If you	wis	h to a	dd additi	tional non-patent literature document citation in	ormation please click the Add b	utton Add		
			•	EXAMINER SIGN	ATURE			
Exan	niner	Signa	gnature /Lynn Bristol/ Date Considered 05/04/2007					
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								
¹ See Kind Codes of USPTO Patent Documents at www.USPTO.GOV or MPEP 901.04. ² Enter office that issued the document, by the two-letter code (WIPO Standard ST.3). ³ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁴ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁵ Applicant is to place a check mark here if English language translation is attached.								

10/516705 DT12 Rec'd PCT/PTC 02 DEC 2004

P1O/SB/08A (08-03)
Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

Sheet 1

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Complete if Known		
Application Number	Based on PCT/JP03/06942	
Filing Date	Int'l Filing 02 JUNE 2003	
First Named Inventor	Takahito HARA	
Art Unit	tba	
Examiner Name	tba	
Attorney Docket Number	3056 USOP	

Examiner	Cite	Document Number	Publication Date	Name of Patentee or	Pages, Columns, Lines, Where
Initials*	Cite No.1	Number-Kind Code ² (# known)	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
LAB	A1	^{US-} 6,291,194 B1	09/18/2001	Taneli Raivio, etal.	
		US-			·
		US-			
-		US-			
		US-			

	FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages			
		Country Code ^{3 "} Number ^{4 "} Kind Code ⁵ (if known)	MM-DD-YYYY		Or Relevant Figures Appear	T°		
						-		
· · · · · · · · · · · · · · · · · · ·								
						L		
,					1			

Examiner Signature	/Lynn Bristol/	Date Considered	05/04/2007

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \(^1\)Applicant's unique citation designation number (optional). \(^2\)See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. \(^3\)Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \(^4\)For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \(^5\)Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \(^8\)Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

1



10/516705 DT 28 ec'd PCT/PTO 0 2 DEC 2004 PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.							
stitute for form 1449/PTO	Complete if Known						
Substitute for form 1443/110	Application Number,	Based on PCT/JP03/06942					

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Filing Date
Int'l Filing 02 JUNE 2003
Takahito HARA

Art Unit
tba

Sheet 2 of 2 Attorney Docket Number 3056 US0P

		NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²		
1 NO A2		MARIANNE D. SADAR, "Androgen-independent Induction of Prostate-specific Antigen Gene Expression via Cross-talk between the Androgen Receptor and Protein Kinase A Signal Transduction Pathways", J. Biol. Chem., (1999), pp. 7777-7783, Vol. 274, No. 12			
	А3	J. VELDSCHOLTE, "A Mutation in the Ligand Binding Domain of the Androgen Receptor of Human INCaP Cells Affects Steroid Binding Characteristics and Response to Anti-Androgens", Biochem. Biophys. Res. Commun., (1990), pp. 534-540, Vol. 173, No. 2.			
	A4	M-E TAPLIN, et al., "Selection for Androgen Receptor Mutations in Prostate Cancers Treated with Androgen Antagonist", Cancer Research, (1999), pp. 2511-2515, Vol. 59, No. 11.			
	A5	M. MARCELLI, et al., "Amino Acid Substitutions in the Hormone-binding Domain of the Human Androgen Receptor Alter the Stability of the Hormone Receptor Complex", J. Clin. Invest. (1994), pp. 1642-1650, Vol. 94, No. 4			
	A6	JAYA P. GADDIPATI, et al., "Frequent Detection of Codon 877 Mutation in the Androgen Receptor Gene in Advanced Prostate Cancers", Cancer Research, (1994), pp. 2861-2864, Vol. 54, No. 11.			
	A7	KYLLIKKI HAAPALA, et al., "Androgen Receptor Alterations in Prostate Cancer Relapsed During a Combined Androgen Blockade by Orchiectomy and Bicalutamide", Laboratory Investigation, (2001), pp. 1647-1651, Vol. 81, No. 12.			
	. A8	JOHN KOKONTIS, et al., "Increased Androgen Receptor Activity and Altered c-myc Expression in Prostate Cancer Cells after Long-Term Androgen Deprivation", Cancer Research, (1994), pp. 1566-1573, Vol. 54.			
W	А9	YOSHIHISA UMEKITA, et al., "Human Prostate Tumor Growth in Athymic Mice: Inhibition by Androgens and Stimulation by Finasteride", Proc. Natl. Acad. Sci. USA, (1996), pp. 11802-11807, Vol. 93.			

Examiner	Delatati	Date	05/04/2007
Signature	/Lynn Bristol/	Considered	00/04/2007
T.3		 	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.